Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | FGF1 | P05230 | 2/20 | 0.45 |
| ▸ | FGF2 | P09038 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 2/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MDK | P21741 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | GJA1 | P17302 | 1/20 | 0.38 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891482 | 1.00 | LGALS8 (0.47) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL16620344 | 1.00 | LGALS8 (0.47) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL29602620 | 0.94 | LGALS8 (0.47) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL15130853 | 0.94 | MMP13 (0.47) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL18132301 | 0.93 | LGALS8 (0.42) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL30891307 | 0.92 | MMP13 (0.46) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL30891274 | 0.92 | LGALS8 (0.41) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL30891273 | 0.92 | MMP13 (0.46) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL30391583 | 0.92 | MMP13 (0.46) | LGALS8FGF1FGF2VEGFAHPSE | |
| SCHEMBL30891312 | 0.92 | MMP13 (0.46) | LGALS8FGF1FGF2VEGFAHPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | LGALS8 615/4885FGF1 1543/4885FGF2 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.